



## Clinical trial results:

**A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis**

### Summary

EudraCT number	2014-003613-28
Trial protocol	AT IS DE DK GB
Global end of trial date	27 January 2016

### Results information

Result version number	v1 (current)
This version publication date	12 February 2017
First version publication date	12 February 2017

### Trial information

#### Trial identification

Sponsor protocol code	CLFX453X2201
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02404389
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 January 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 January 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objectives of the study were i) to assess tolerability and safety of LFX453 in patients with actinic keratosis (AK) and ii) to assess efficacy of LFX453 compared to vehicle in patients with actinic keratosis.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 6
Country: Number of subjects enrolled	Denmark: 15
Country: Number of subjects enrolled	Germany: 41
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Iceland: 19
Worldwide total number of subjects	82
EEA total number of subjects	82

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	18
From 65 to 84 years	64
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 82 patients, male and female of non-childbearing potential aged 18-75 years, with Actinic Keratosis (AK) on the face or balding scalp were enrolled in the study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	LFX453 0.1% NMC

Arm description:

LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications

Arm type	Experimental
Investigational medicinal product name	LFX453
Investigational medicinal product code	LFX453
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

LFX453 nanomedicinal cream (NMC) 0.1% apply twice daily topically

<b>Arm title</b>	LFX453 0.15% LCC
------------------	------------------

Arm description:

LFX453 0.15% liquid crystal cream (LCC) Twice daily applications

Arm type	Experimental
Investigational medicinal product name	LFX453
Investigational medicinal product code	LFX453
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

LFX453 liquid crystal cream (LCC) 0.15% apply twice daily topically

<b>Arm title</b>	Vehicle to NMC
------------------	----------------

Arm description:

Vehicle to nanomedicinal cream (NMC) Twice daily applications

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	LFX453
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

vehicle to nanomedicinal cream (NMC) apply twice daily topically

<b>Arm title</b>	Vehicle to LCC
Arm description: Vehicle to liquid crystal cream (LCC) Twice daily applications	
Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	LFX453
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

vehicle to liquid crystal cream (LCC) apply twice daily topically

<b>Arm title</b>	Aldara
Arm description: Aldara cream 3 applications per week	
Arm type	Active comparator
Investigational medicinal product name	imiquimod
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Aldara® 5% cream apply 3 days per week topically

<b>Number of subjects in period 1</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Vehicle to NMC
Started	20	20	11
Completed	18	20	10
Not completed	2	0	1
Adverse event, non-fatal	1	-	1
Subject/guardian decision	1	-	-

<b>Number of subjects in period 1</b>	Vehicle to LCC	Aldara
Started	10	21
Completed	9	18
Not completed	1	3
Adverse event, non-fatal	-	2
Subject/guardian decision	1	1



## Baseline characteristics

<b>Reporting groups</b>	
Reporting group title	LFX453 0.1% NMC
Reporting group description: LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications	
Reporting group title	LFX453 0.15% LCC
Reporting group description: LFX453 0.15% liquid crystal cream (LCC) Twice daily applications	
Reporting group title	Vehicle to NMC
Reporting group description: Vehicle to nanomedicinal cream (NMC) Twice daily applications	
Reporting group title	Vehicle to LCC
Reporting group description: Vehicle to liquid crystal cream (LCC) Twice daily applications	
Reporting group title	Aldara
Reporting group description: Aldara cream 3 applications per week	

<b>Reporting group values</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Vehicle to NMC
Number of subjects	20	20	11
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	7	4	2
From 65-84 years	13	16	9
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	67.7	68.6	68.3
standard deviation	± 5.23	± 6.25	± 6.66
Gender, Male/Female Units: Subjects			
Female	5	2	0
Male	15	18	11

<b>Reporting group values</b>	Vehicle to LCC	Aldara	Total
Number of subjects	10	21	82
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0

Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1	4	18
From 65-84 years	9	17	64
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	70.2	68.6	
standard deviation	± 4.32	± 5.61	-
Gender, Male/Female			
Units: Subjects			
Female	2	0	9
Male	8	21	73

### Subject analysis sets

Subject analysis set title	Combined Vehicle
Subject analysis set type	Full analysis

Subject analysis set description:

Vehicle to nanomedicinal cream (NMC) and Vehicle to liquid crystal cream (LCC) Twice daily applications

Reporting group values	Combined Vehicle		
Number of subjects	21		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	3		
From 65-84 years	18		
85 years and over	0		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	±		
Gender, Male/Female			
Units: Subjects			
Female	2		
Male	19		

## End points

### End points reporting groups

Reporting group title	LFX453 0.1% NMC
Reporting group description:	LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
Reporting group title	LFX453 0.15% LCC
Reporting group description:	LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
Reporting group title	Vehicle to NMC
Reporting group description:	Vehicle to nanomedicinal cream (NMC) Twice daily applications
Reporting group title	Vehicle to LCC
Reporting group description:	Vehicle to liquid crystal cream (LCC) Twice daily applications
Reporting group title	Aldara
Reporting group description:	Aldara cream 3 applications per week
Subject analysis set title	Combined Vehicle
Subject analysis set type	Full analysis
Subject analysis set description:	Vehicle to nanomedicinal cream (NMC) and Vehicle to liquid crystal cream (LCC) Twice daily applications

### Primary: Number of adverse events (AE)/Serious Adverse Events (SAE) as a measure of safety and tolerability up to 20 weeks

End point title	Number of adverse events (AE)/Serious Adverse Events (SAE) as a measure of safety and tolerability up to 20 weeks <sup>[1]</sup>
End point description:	Number of participants with at least one AE/SAE in the category up to 20 weeks
End point type	Primary
End point timeframe:	20 weeks

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this primary outcome.

End point values	LFX453 0.1% NMC	LFX453 0.15% LCC	Vehicle to NMC	Vehicle to LCC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	20	11	10
Units: participants				
Adverse Events (AEs)	10	15	9	8
Serious Adverse Events (SAEs)	1	1	1	1

End point values	Aldara			
Subject group type	Reporting group			
Number of subjects analysed	21			

Units: participants				
Adverse Events (AEs)	18			
Serious Adverse Events (SAEs)	1			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants that had Complete clearance of Actinic keratosis (AK) at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined

End point title	Number of Participants that had Complete clearance of Actinic keratosis (AK) at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined <sup>[2]</sup>
End point description:	Complete clearance of Actinic keratosis (AK), defined as the number of patients with a count of zero lesions in the treated area, evaluated 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined
End point type	Primary
End point timeframe:	Week 20
Notes:	[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: End point was provided for the arms that were part of this objective and not all baseline period arms

End point values	LFX453 0.1% NMC	LFX453 0.15% LCC	Combined Vehicle	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	20	20	21	
Units: participants	1	1	1	

## Statistical analyses

Statistical analysis title	LFX453 0.1% NMC versus Combined Vehicle
Comparison groups	LFX453 0.1% NMC v Combined Vehicle
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[3]</sup>
P-value	= 0.515
Method	Posterior mean
Parameter estimate	Mean difference (net)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.12
upper limit	0.12

Variability estimate	Standard deviation
Dispersion value	0.07

Notes:

[3] - There was no difference in the posterior mean in the complete clearance rate between LFX453 NMC and the combined vehicle group, since the posterior distribution for the difference in complete clearance rate did not reach a 90% chance of being positive (probability =0.515).

<b>Statistical analysis title</b>	LFX453 0.15% LCC versus Combined Vehicle
Comparison groups	LFX453 0.15% LCC v Combined Vehicle
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[4]</sup>
P-value	= 0.517
Method	posterior mean
Parameter estimate	Mean difference (net)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.12
upper limit	0.13
Variability estimate	Standard deviation
Dispersion value	0.07

Notes:

[4] - There was no difference in the posterior mean in the complete clearance rate between LFX453 LCC and the combined vehicle group, since the posterior distribution for the difference in complete clearance rate did not reach a 90% chance of being positive (probability =0.517).

**Primary: Reduction rate (percent) of Actinic keratosis (AK) lesion count at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined**

End point title	Reduction rate (percent) of Actinic keratosis (AK) lesion count at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined <sup>[5][6]</sup>
-----------------	--

End point description:

Reduction rate (percent) of Actinic keratosis (AK) lesion count at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined

End point type	Primary
----------------	---------

End point timeframe:

Week 20

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this primary outcome.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: End point was provided for the arms that were part of this objective and not all baseline period arms

<b>End point values</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Combined Vehicle	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	20	20	21	
Units: lesion count				
arithmetic mean (standard deviation)	33.2 (± 31.19)	34.5 (± 33.2)	34.3 (± 33.31)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants that had Complete clearance of Actinic keratosis (AK) at Week 8 and Week 16 for LFX453 compared to vehicle groups combined

End point title	Number of Participants that had Complete clearance of Actinic keratosis (AK) at Week 8 and Week 16 for LFX453 compared to vehicle groups combined <sup>[7]</sup>
-----------------	--

End point description:

Complete clearance of Actinic keratosis (AK), defined as the number of patients with a count of zero lesions in the treated area, evaluated at week 8 and Week 16 for LFX453 compared to vehicle groups combined

End point type	Secondary
----------------	-----------

End point timeframe:

week 8, week 16

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: End point was provided for the arms that were part of this objective and not all baseline period arms

End point values	LFX453 0.1% NMC	LFX453 0.15% LCC	Combined Vehicle	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	20	20	21	
Units: participants				
Week 8	0	0	1	
Week 16	1	1	1	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants that had Partial clearance of Actinic keratosis (AK) at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined

End point title	Number of Participants that had Partial clearance of Actinic keratosis (AK) at 8 weeks after the end of treatment (Week 20) for LFX453 compared to vehicle groups combined <sup>[8]</sup>
-----------------	---

End point description:

Partial clearance of Actinic keratosis (AK), the defined as proportion of patients with at least 75% reduction in the number of AK lesion count compared to baseline, evaluated at 8 weeks after the end of treatment (Week 20 = EOS visit) for LFX453 compared to vehicle groups combined

End point type	Secondary
----------------	-----------

End point timeframe:

Week 20

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: End point was provided for the arms that were part of this objective and not all baseline period arms

<b>End point values</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Combined Vehicle	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	20	20	21	
Units: participants	1	2	2	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants that Partial clearance of Actinic keratosis (AK) at at Week 8 and Week 16 for LFX453 compared to vehicle groups combined

End point title	Number of Participants that Partial clearance of Actinic keratosis (AK) at at Week 8 and Week 16 for LFX453 compared to vehicle groups combined <sup>[9]</sup>
-----------------	--

End point description:

Partial clearance of Actinic keratosis (AK), the defined as proportion of patients with at least 75% reduction in the number of AK lesion count compared to baseline, evaluated at week 8 and Week 16 for LFX453 compared to vehicle groups combined

End point type	Secondary
----------------	-----------

End point timeframe:

week 8, week 16

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: End point was provided for the arms that were part of this objective and not all baseline period arms

<b>End point values</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Combined Vehicle	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	20	20	21	
Units: participants				
Week 8	1	0	3	
Week 16	3	4	3	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Reduction rate (percent) of Actinic keratosis (AK) lesion count at Week 8 for LFX453 compared to vehicle groups combined

End point title	Reduction rate (percent) of Actinic keratosis (AK) lesion count at Week 8 for LFX453 compared to vehicle groups combined <sup>[10]</sup>
-----------------	--

---

End point description:

Reduction rate (percent) of Actinic keratosis (AK) lesion count at Week 8 for LFX453 compared to vehicle groups combined

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Week 8

---

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: End point was provided for the arms that were part of this objective and not all baseline period arms

<b>End point values</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Combined Vehicle	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	20	20	21	
Units: lesion count				
arithmetic mean (standard deviation)	21.9 (± 36.18)	21.9 (± 28.91)	32.3 (± 33.55)	

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit

Assessment type	Systematic
<b>Dictionary used</b>	
Dictionary name	MedDRA
Dictionary version	18.1
<b>Reporting groups</b>	
Reporting group title	LFX453 0.1% NMC
Reporting group description: LFX453 0.1% NMC	
Reporting group title	LFX453 0.15% LCC
Reporting group description: LFX453 0.15% LCC	
Reporting group title	Vehicle NMC
Reporting group description: Vehicle NMC	
Reporting group title	Vehicle LCC
Reporting group description: Vehicle LCC	
Reporting group title	Aldara
Reporting group description: Aldara	

<b>Serious adverse events</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Vehicle NMC
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	1 / 11 (9.09%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
FEMORAL NECK FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>CEREBRAL INFARCTION</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL HERNIA</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DIARRHOEA</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Psychiatric disorders</b>			
<b>DEPRESSION</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>			
<b>Vehicle LCC</b>			
<b>Aldara</b>			
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	1 / 10 (10.00%)	1 / 21 (4.76%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
<b>Injury, poisoning and procedural complications</b>			
<b>FEMORAL NECK FRACTURE</b>			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>ATRIAL FIBRILLATION</b>			

subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>CEREBRAL INFARCTION</b>			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL HERNIA</b>			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIARRHOEA</b>			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Psychiatric disorders</b>			
<b>DEPRESSION</b>			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	LFX453 0.1% NMC	LFX453 0.15% LCC	Vehicle NMC
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	10 / 20 (50.00%)	14 / 20 (70.00%)	9 / 11 (81.82%)
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>BASAL CELL CARCINOMA</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
<b>SEBORRHOEIC KERATOSIS</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0

Vascular disorders			
HAEMATOMA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
HYPERTENSION			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
THROMBOSIS			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
APPLICATION SITE COLDNESS			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
APPLICATION SITE ERYTHEMA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
APPLICATION SITE PRURITUS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
APPLICATION SITE SCAB			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
CHILLS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
FATIGUE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
HYPOTHERMIA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
NON-CARDIAC CHEST PAIN			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
RHINITIS ALLERGIC subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
Psychiatric disorders AGITATION subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
BURNOUT SYNDROME subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
Investigations ANTIPSYCHOTIC DRUG LEVEL INCREASED subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
BLOOD CREATININE INCREASED subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 11 (9.09%) 1
GAMMA-GLUTAMYLTRANSFERASE INCREASED subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
LYMPHOCYTE COUNT DECREASED subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
Injury, poisoning and procedural complications CONTUSION subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
CORNEAL ABRASION			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
<b>EYELID INJURY</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
<b>HEAD INJURY</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
<b>LACERATION</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
<b>MUSCLE RUPTURE</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
<b>PERIORBITAL HAEMATOMA</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
<b>RIB FRACTURE</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
<b>Nervous system disorders</b>			
<b>AUTONOMIC NERVOUS SYSTEM IMBALANCE</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
<b>BURNING SENSATION</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
<b>DIZZINESS</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
<b>HEADACHE</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
<b>POLYNEUROPATHY</b>			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
POOR QUALITY SLEEP subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
SCIATICA subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
Blood and lymphatic system disorders HAEMOLYTIC ANAEMIA subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
INCREASED TENDENCY TO BRUISE subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
Ear and labyrinth disorders VERTIGO subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 11 (9.09%) 1
VESTIBULAR DISORDER subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
Eye disorders BLEPHARITIS subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
Gastrointestinal disorders ABDOMINAL PAIN subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
APHTHOUS ULCER subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
APICAL GRANULOMA			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
<b>DIARRHOEA</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	3 / 20 (15.00%) 3	0 / 11 (0.00%) 0
<b>GASTROESOPHAGEAL REFLUX DISEASE</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 11 (9.09%) 1
<b>NAUSEA</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 11 (9.09%) 1
<b>TOOTHACHE</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
<b>Hepatobiliary disorders</b>			
<b>CHOLELITHIASIS</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>BLISTER</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
<b>DRY SKIN</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
<b>ECZEMA</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
<b>ERYTHEMA</b>			
subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
<b>PAIN OF SKIN</b>			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
<b>SKIN EXFOLIATION</b>			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
Renal and urinary disorders RENAL CYST subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 11 (9.09%) 1
Musculoskeletal and connective tissue disorders ARTHRALGIA subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
BACK PAIN subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	1 / 11 (9.09%) 1
MUSCLE SPASMS subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
MYALGIA subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
MYOSCLEROSIS subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
NECK PAIN subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	0 / 11 (0.00%) 0
OSTEOARTHRITIS subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 20 (5.00%) 1	1 / 11 (9.09%) 2
PERIARTHRITIS subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 11 (0.00%) 0
Infections and infestations			

<b>BRONCHITIS</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
<b>CYSTITIS</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
<b>EYE INFECTION</b>			
subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
<b>GASTROENTERITIS</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
<b>INFLUENZA</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
<b>NASOPHARYNGITIS</b>			
subjects affected / exposed	1 / 20 (5.00%)	5 / 20 (25.00%)	3 / 11 (27.27%)
occurrences (all)	1	6	3
<b>ORAL HERPES</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
<b>PNEUMONIA</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
<b>RELAPSING FEVER</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
<b>SINUSITIS</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
<b>TINEA PEDIS</b>			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
<b>Metabolism and nutrition disorders</b>			
<b>HYPOKALAEMIA</b>			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Vehicle LCC	Aldara	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 10 (80.00%)	17 / 21 (80.95%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	2	
SEBORRHOEIC KERATOSIS			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Vascular disorders			
HAEMATOMA			
subjects affected / exposed	1 / 10 (10.00%)	1 / 21 (4.76%)	
occurrences (all)	1	1	
HYPERTENSION			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
THROMBOSIS			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
APPLICATION SITE COLDNESS			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
APPLICATION SITE ERYTHEMA			
subjects affected / exposed	0 / 10 (0.00%)	5 / 21 (23.81%)	
occurrences (all)	0	6	
APPLICATION SITE PRURITUS			
subjects affected / exposed	1 / 10 (10.00%)	2 / 21 (9.52%)	
occurrences (all)	1	2	
APPLICATION SITE SCAB			
subjects affected / exposed	0 / 10 (0.00%)	2 / 21 (9.52%)	
occurrences (all)	0	3	

CHILLS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
FATIGUE			
subjects affected / exposed	0 / 10 (0.00%)	2 / 21 (9.52%)	
occurrences (all)	0	2	
HYPOTHERMIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 10 (0.00%)	3 / 21 (14.29%)	
occurrences (all)	0	3	
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
RHINITIS ALLERGIC			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
AGITATION			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
BURNOUT SYNDROME			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Investigations			
ANTIPSYCHOTIC DRUG LEVEL INCREASED			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	

GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
LYMPHOCYTE COUNT DECREASED			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
CORNEAL ABRASION			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
EYELID INJURY			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
HEAD INJURY			
subjects affected / exposed	1 / 10 (10.00%)	1 / 21 (4.76%)	
occurrences (all)	1	1	
LACERATION			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
MUSCLE RUPTURE			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
PERIORBITAL HAEMATOMA			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
RIB FRACTURE			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
Nervous system disorders			
AUTONOMIC NERVOUS SYSTEM IMBALANCE			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	

BURNING SENSATION			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
DIZZINESS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
HEADACHE			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	2	
POLYNEUROPATHY			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
POOR QUALITY SLEEP			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
SCIATICA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
HAEMOLYTIC ANAEMIA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
INCREASED TENDENCY TO BRUISE			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
VERTIGO			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
VESTIBULAR DISORDER			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
BLEPHARITIS			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			

ABDOMINAL PAIN			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
APHTHOUS ULCER			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
APICAL GRANULOMA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
DIARRHOEA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
NAUSEA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
TOOTHACHE			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
Hepatobiliary disorders			
CHOLELITHIASIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
BLISTER			
subjects affected / exposed	0 / 10 (0.00%)	1 / 21 (4.76%)	
occurrences (all)	0	1	
DRY SKIN			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	
ECZEMA			

subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 21 (0.00%) 0	
<b>ERYTHEMA</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>PAIN OF SKIN</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>SKIN EXFOLIATION</b> subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 21 (4.76%) 1	
<b>Renal and urinary disorders</b> <b>RENAL CYST</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>Musculoskeletal and connective tissue disorders</b> <b>ARTHRALGIA</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>BACK PAIN</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>MUSCLE SPASMS</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>MYALGIA</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>MYOSCLEROSIS</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>NECK PAIN</b> subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>OSTEOARTHRITIS</b>			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>PAIN IN EXTREMITY</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>PERIARTHROSIS</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>Infections and infestations</b>			
<b>BRONCHITIS</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>CYSTITIS</b>			
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 21 (0.00%) 0	
<b>EYE INFECTION</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>GASTROENTERITIS</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>INFLUENZA</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>NASOPHARYNGITIS</b>			
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 21 (4.76%) 1	
<b>ORAL HERPES</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 21 (0.00%) 0	
<b>PNEUMONIA</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	
<b>RELAPSING FEVER</b>			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 21 (4.76%) 1	

SINUSITIS			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
TINEA PEDIS			
subjects affected / exposed	0 / 10 (0.00%)	0 / 21 (0.00%)	
occurrences (all)	0	0	
Metabolism and nutrition disorders			
HYPOKALAEMIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 21 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 September 2014	Amendment 1 (issued before patient enrollment started) was generated as a result of a change in the storage conditions of the study drug. The major change to the protocol was the description of study drug handling when administered to the patient in Protocol Section 3.1. Minor typos were corrected and imiquimod 5% cream specified to Aldara® to reflect actual plans. The changes included in this amendment did not influence the population or design of the study.
27 January 2015	Amendment 2 was generated to implement requests received from Health Authorities (HAs) and ethics committees (ECs) primarily to repeat pregnancy tests throughout the treatment period of the study, ensure that patients included were not under any influence from study staff, and included information to instruct patients to minimize exposure of the treated areas to UV light or sunlight. The changes included in this amendment did not influence the patient safety or scientific value of this study. The amendment was considered to be non-substantial.
15 September 2015	Amendment 3 was developed to clarify the analyses time point considered for the interim and final analysis of the primary and secondary endpoints given the fact that patients could achieve complete clearance already at the end of the first of 4-week treatment. The specific length of treatment duration (2 cycles of 4-week treatment) was removed to allow patients with complete clearance after one treatment cycle to be included in the analysis. The opportunity was also taken to clarify the exclusion criterion #7 and the location of biopsies. The frequent association of Bowen's disease in these patients was not foreseen and therefore could constitute an exclusion criterion based on the previous wording of exclusion criterion #7. The exclusion criterion #7 was revised to clarify that patients with Bowen's disease shall not be excluded, similarly to patients with basal cell carcinoma of the skin or in-situ cervical cancer. The changes described in this amended protocol were substantial and required IRB/IEC approval prior to implementation. In addition, if the changes herein affected the Informed Consent, sites were required to update and submit for approval a revised Informed Consent that took into account the changes described in this amended protocol. These amendments were not considered to have affected the interpretation of study results as they were minor and occurred prior to study unblinding.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported